|
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Clinical research trials and Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer. Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer clinical trial. Subjects frequently get the best healthcare possible for their Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer  Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
For Condition: recurrent non-small cell lung cancer,stage 3B non-small cell lung cancer,stage 4 non-small cell lung cancer,squamous cell lung cancer,large cell lung cancer,adenosquamous cell lung cancer,adenocarcinoma of the lung
Status: No longer recruiting
Sponsor(s): Tularik ,
Synopsis: RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol. Combining lometrexol with folic acid may be an effective treatment for non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combining lometrexol with folic acid in treating patients who have stage IIIB or stage IV non-small cell lung cancer that has been previously treated.
Details: OBJECTIVES: I. Determine the overall response rate in patients with previously treated stage IIIB or IV non-small cell lung cancer when treated with lometrexol and folic acid. II. Determine the complete response rate, duration of response, and time to progression in patients treated with this regimen. III. Determine the 1-year survival rate and overall survival in patients treated with this regimen. IV. Determine the safety profile of this regimen in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patients receive oral folic acid once daily on days -7 to 6. Patients also receive lometrexol IV over 30-60 seconds on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed up to 2 months after removal from study and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 50-100 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed non-small cell lung cancer (NSCLC) - Stage IIIB or IV [*Squamous cell carcinoma *Adenocarcinoma *Large cell carcinoma *Adenosquamous carcinoma] Progressive disease after receiving 1 cisplatin- or carboplatin-containing regimen for stage IIIB or IV disease Measurable disease - At least 1 lesion at least 1 cm x 1 cm by CT scan either not in a previously irradiated field or showing clear evidence of disease progression after radiation No symptomatic or rapidly increasing, moderate or large amounts of pleural effusion or ascites No prior or concurrent CNS metastases (brain or meningeal) --Prior/Concurrent Therapy-- Biologic therapy: - At least 3 weeks since prior biologic therapy for NSCLC and recovered from acute side effects - Prior treatment with an experimental vaccine allowed - No concurrent routine or prophylactic filgrastim (G-CSF), sargramostim (GM- CSF), or epoetin alfa Chemotherapy: - See Disease Characteristics - At least 3 weeks since prior chemotherapy for NSCLC (6 weeks for mitomycin or nitrosourea) and recovered from acute side effects - Prior adjuvant or neoadjuvant chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: - See Disease Characteristics - Recovered from acute side effects of prior radiotherapy - No prior radiotherapy to 25% or more of bone marrow - No prior whole pelvic irradiation Surgery: At least 3 weeks since prior major surgery and recovered Other: - At least 3 weeks since prior investigational agent - No concurrent proguanil, trimethoprim, co-trimoxazole, or pyrimethamine --Patient Characteristics-- Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: At least 3 months Hematopoietic: - Absolute neutrophil count at least 1,500/mm3* - Platelet count at least 100,000/mm3* - Hemoglobin at least 9.0 g/dL* *Without transfusions or growth factors in the previous 7 days Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) (regardless of liver involvement secondary to tumor) - AST and ALT no greater than 2.5 times ULN (5 times ULN if liver has tumor involvement) Renal: Calculated creatinine clearance at least 60 mL/min using Cockroft and Gault formula Gastrointestinal: - No inflammatory bowel disease - No radiation enteritis - No malabsorption syndrome - No inability to absorb folic acid Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during study - No known untreated vitamin B12 deficiency - HIV negative - No drug abusers - No prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No severe concurrent disease or major comorbidity that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SeanMcCarthy, Study Chair, Tularik
U.S. Oncology Research Inc.
Houston, Texas, 77060
United States
US Oncology - Albany Regional Cancer Center
Albany, New York, 12208
United States
Cancer Care Northwest
Spokane, Washington, 99202
United States
Cancer Centers of Florida (U.S. Oncology)
Orlando, Florida, 32806
United States
Louisiana State University School of Medicine
New Orleans, Louisiana, 70112-2822
United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128
United States
Tyler Cancer Center
Tyler, Texas, 75702
United States
Additional Information:
Study ID Numbers: CDR0000069316; USO-01103,TULA-T064031
Study Start Date: February 2002
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00033722
Other Adenosquamous Cell Lung Cancer Studies:
1. Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
2. Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
3. Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
4. Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
5. Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Related Studies:
Other adenosquamous cell lung cancer Clinical Trials
Other New York Clinical Trials
Other Albany Clinical Trials
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
